Skip to content
Screener

Arvinas ARVN Business Segments — Non program-specific external expense

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNReportable Segment — Total external development program expenses
$27.68M+68.4%
Martin Marietta Materials logo
MLMReportable Segments — External Freight Expense
$103M+37.3%
LanzaTech Global, Inc. logo
LNZAReportable Segment — External Service Providers Expenses
$3.55M-63.0%
Sionna Therapeutics logo
SIONReportable Segment — External research and development expense
$12.93M+29.6%
LQD
LQDASingle Reportable — Non Program Expenses
$6.2M+64.4%
Allogene Therapeutics logo
ALLOReportable Segment — Supporting external spend
$4.37M-25.2%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept arvn:ResearchAndDevelopmentExpenseNonProgramSpecific.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
ARV-3933.72.6
Bavdegalutamide (ARV-110)0.21.1
Other programs2.61.7
Non program-specific external expense9.213.9
Compensation and related personnel expense(including stock-based compensation)21.336.9
Other research and development expense2.43.1
Total research and development expense60.390.8
General and administrative expense19.126.6

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's business segments — non program-specific external expense?
Arvinas (ARVN) reported business segments — non program-specific external expense of $9.2M in Q1 2026.
How has Arvinas's business segments — non program-specific external expense changed year-over-year?
Arvinas's business segments — non program-specific external expense decreased by 33.8% year-over-year, from $13.9M to $9.2M.
What is the long-term trend for Arvinas's business segments — non program-specific external expense?
Over 3 years (2022 to 2025), Arvinas's business segments — non program-specific external expense has grown at a -8.7% compound annual growth rate (CAGR), from $64.3M to $49M.
What does business segments — non program-specific external expense mean?
These are external costs incurred by the segment that are not directly attributable to a specific research or development program. Monitoring these expenses helps assess the overhead and infrastructure costs required to support the broader research organization.

Ask your AI about Arvinas's business segments — non program-specific external expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude